GCM
AUPH icon

Gables Capital Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Gables Capital Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-850
Closed -$6K – 350
2019
Q2 		$6K Hold
850
– – ﹤0.01% 299
2019
Q1 		$6K Hold
850
– – ﹤0.01% 305
2018
Q4 		$6K Hold
850
– – 0.01% 301
2018
Q3 		$6K Hold
850
– – ﹤0.01% 312
2018
Q2 		$5K Buy
+850
New +$4.74K ﹤0.01% 322

Other funds holding AUPH

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Gables Capital Management's AUPH Position: Q3 2019 in Review

Gables Capital Management sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2019, closing a stake of 850 shares — an estimated $6K sold.

Gables Capital Management first reported a position in AUPH in Q2 2018 and held it in 5 quarters. The position peaked at $6K in Q2 2019. 72 funds tracked by Wall St. Rank hold AUPH as of Q3 2019.

  • Gables Capital Management reported no remaining Aurinia Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Gables Capital Management sold 850 Aurinia Pharmaceuticals shares in Q3 2019, an estimated $6K.
  • Gables Capital Management first reported a position in Aurinia Pharmaceuticals in Q2 2018 and held it in 5 quarters.
  • Gables Capital Management's Aurinia Pharmaceuticals position peaked at $6K in Q2 2019.
  • 72 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2019.

Based on Gables Capital Management's 13F filing for Q3 2019, filed 30 Oct 2019.